San Francisco, California, United States
Contact Info
2K followers
500+ connections
San Francisco, California, United States
Contact Info
2K followers
500+ connections
Activity
-
Proud of the ARS Pharma team for coming up with neffy and getting it approved! Grateful for support from the patient community, board members and…
Proud of the ARS Pharma team for coming up with neffy and getting it approved! Grateful for support from the patient community, board members and…
Liked by Josh Richardson
-
Great to talk AI for drug discovery Andrew Ross Sorkin on CNBC. There is no more impactful use of AI than improving human health. Delighted for the…
Great to talk AI for drug discovery Andrew Ross Sorkin on CNBC. There is no more impactful use of AI than improving human health. Delighted for the…
Liked by Josh Richardson
-
Grateful to partner with this incredible syndicate of new and existing investors in our $120mm Series B financing. In a challenging market, we are…
Grateful to partner with this incredible syndicate of new and existing investors in our $120mm Series B financing. In a challenging market, we are…
Liked by Josh Richardson
Experience & Education
More activity by Josh
-
We've got two awesome Portrait panels lined up for SXSW. Vote below! "The New 51%: Building Careers in Entertainment and Beyond" with costume…
We've got two awesome Portrait panels lined up for SXSW. Vote below! "The New 51%: Building Careers in Entertainment and Beyond" with costume…
Liked by Josh Richardson
-
A couple of years ago, when Lucian Iancovici MD John Schilling Matthew Hobart invited me and Shinichiro Fuse to join TPG to build this inaugural Life…
A couple of years ago, when Lucian Iancovici MD John Schilling Matthew Hobart invited me and Shinichiro Fuse to join TPG to build this inaugural Life…
Liked by Josh Richardson
-
🚨 Congrats to Outpace Bio for their Series B raise of $144 million led by RA Capital Management. This funding helps advance a groundbreaking new…
🚨 Congrats to Outpace Bio for their Series B raise of $144 million led by RA Capital Management. This funding helps advance a groundbreaking new…
Liked by Josh Richardson
-
Excited to share the news of Jnana Therapeutics' acquisition by Otsuka Pharmaceutical Co., Ltd. for up to $1.125B. It's especially meaningful because…
Excited to share the news of Jnana Therapeutics' acquisition by Otsuka Pharmaceutical Co., Ltd. for up to $1.125B. It's especially meaningful because…
Liked by Josh Richardson
-
I’m excited to welcome Charles Baum, MD, PhD to Terremoto Biosciences – his extensive leadership experience in small molecule therapeutics and drug…
I’m excited to welcome Charles Baum, MD, PhD to Terremoto Biosciences – his extensive leadership experience in small molecule therapeutics and drug…
Liked by Josh Richardson
-
Today marks a significant milestone in the next chapter (or arc) of my career. After retiring from J&J as the Global Head of Oncology R&D in January,…
Today marks a significant milestone in the next chapter (or arc) of my career. After retiring from J&J as the Global Head of Oncology R&D in January,…
Liked by Josh Richardson
-
Delighted to announce the unveiling of our latest company creation with the (very oversubscribed) $165M Series A of Third Arc Bio. Opening credits:…
Delighted to announce the unveiling of our latest company creation with the (very oversubscribed) $165M Series A of Third Arc Bio. Opening credits:…
Liked by Josh Richardson
-
CatalYm GmbH, a Jeito company based in Munich, closed today a new 150 mio $ oversubscribed financing round. Big congratulations to CEO Phil…
CatalYm GmbH, a Jeito company based in Munich, closed today a new 150 mio $ oversubscribed financing round. Big congratulations to CEO Phil…
Liked by Josh Richardson
-
Honored to lead Cardurion Pharmaceuticals' oversubscribed $260M Series B round alongside existing investor Bain Capital Life Sciences Fund LP and new…
Honored to lead Cardurion Pharmaceuticals' oversubscribed $260M Series B round alongside existing investor Bain Capital Life Sciences Fund LP and new…
Liked by Josh Richardson
-
Pleased to announce that Blue Owl will significantly expand our alternative credit and asset-based finance capabilities with the acquisition of…
Pleased to announce that Blue Owl will significantly expand our alternative credit and asset-based finance capabilities with the acquisition of…
Liked by Josh Richardson
-
Significant news from Kytopen today as its Flowfect(TM) platform moves towards use in a clinical program. This game changing and non viral cell…
Significant news from Kytopen today as its Flowfect(TM) platform moves towards use in a clinical program. This game changing and non viral cell…
Liked by Josh Richardson
-
Proud to speak at the 24th Annual Sachs Biotech in Europe Forum in Basel, Switzerland the Innovation hotspot in the Center of Europe
Proud to speak at the 24th Annual Sachs Biotech in Europe Forum in Basel, Switzerland the Innovation hotspot in the Center of Europe
Liked by Josh Richardson
-
With the rise of advanced therapies, pharma companies are increasingly turning to outsourced partners to bring life-saving drugs to market at…
With the rise of advanced therapies, pharma companies are increasingly turning to outsourced partners to bring life-saving drugs to market at…
Liked by Josh Richardson
Other similar profiles
Explore collaborative articles
We’re unlocking community knowledge in a new way. Experts add insights directly into each article, started with the help of AI.
Explore MoreOthers named Josh Richardson in United States
646 others named Josh Richardson in United States are on LinkedIn
See others named Josh Richardson